ACS chemical neuroscience molecule spotlight on Suvorexant

Corey R Hopkins

doi:10.1021/cn300086a

ACS chemical neuroscience molecule spotlight on Suvorexant

ACS Chem Neurosci. 2012 Sep 19;3(9):647-8. doi: 10.1021/cn300086a.

Author

Corey R Hopkins¹

Affiliation

¹ Vanderbilt Center for Neuroscience Drug Discovery, Department of Pharmacology and Chemistry, Vanderbilt University Medical Center, Vanderbilt University , Nashville, Tennessee 37232-6600, USA.

Abstract

Suvorexant is a dual orexin antagonist currently in Phase III clinical trials for the modulation of sleep and is being developed by Merck. Recent Phase III results showed that patients taking the drug fell asleep faster and slept longer than those on placebo.

Publication types

Review

MeSH terms

Animals
Azepines / pharmacology*
Azepines / therapeutic use
Clinical Trials, Phase I as Topic
Clinical Trials, Phase III as Topic
Humans
Hypnotics and Sedatives / pharmacology*
Hypnotics and Sedatives / therapeutic use
Intracellular Signaling Peptides and Proteins / antagonists & inhibitors
Intracellular Signaling Peptides and Proteins / physiology
Neuropeptides / antagonists & inhibitors
Neuropeptides / physiology
Orexins
Sleep Initiation and Maintenance Disorders / drug therapy*
Triazoles / pharmacology*
Triazoles / therapeutic use
gamma-Aminobutyric Acid / physiology

Substances

Azepines
Hypnotics and Sedatives
Intracellular Signaling Peptides and Proteins
Neuropeptides
Orexins
Triazoles
suvorexant
gamma-Aminobutyric Acid